Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2017

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer

K. Bendjama, E. Quéméneur Human Vaccines and Immunotherapeutics, August 2017 – Read the article Publication

Published 26 August 2017
Categorized as 2017, Myvac, Publication, publication key en, TG4050

First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer

PR Pexa-Vec nivo EN

Published 31 July 2017
Categorized as 2017, Pexa-Vec, Press release

Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy

Laetitia Fend, et al. Cancer Research, July 2017, DOI: 10.1158/0008-5472.CAN-16-2165 – Download the article Publication

Published 24 July 2017
Categorized as -others, 2017, Publication, TG6002

Transgene Announces Cancer Research Publication Confirming the Potential of its Next Generation Armed Engineered Oncolytic Virus

20170724 PR CancerResearch

Published 24 July 2017
Categorized as 2017, Press release

Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T.

20170629 Servier Transgene EN

Published 29 June 2017
Categorized as 2017, Press release

Transgene Hosts Immuno-Oncology R&D Day Focused on Modulating the Tumor Micro-Environment in Paris

20170622 CP RD Day EN

Published 22 June 2017
Categorized as 2017, Press release

Combined General Meeting of June 8, 2017

20170608 TG AGM June 2017 EN

Published 8 June 2017
Categorized as 2017, Press release

TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma

Ahmed Idbaih, et al. ASCO 2017, June 2017 – Download the abstract Abstract

Published 5 June 2017
Categorized as -others, 2017, Publication, TG6002

€50.7 Million in Cash and Cash Equivalents as of March 31, 2017

20170425 PR Q1-2017

Published 25 April 2017
Categorized as 2017, Press release

Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer

20170425 BMS-Clinical Collaboration Release Transgene-FINAL

Published 25 April 2017
Categorized as 2017, Press release, TG4010

Posts pagination

Newer posts Page 1 … Page 3 … Page 5 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu